{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T07:00:14Z","timestamp":1776063614086,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["33IC30_166872"],"award-info":[{"award-number":["33IC30_166872"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ahj.2022.01.010","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T15:34:24Z","timestamp":1643384064000},"page":"33-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS) - A phase II, randomized, double-blind, multi-center, placebo-controlled trial"],"prefix":"10.1016","volume":"247","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7726-4421","authenticated-orcid":false,"given":"Roland","family":"Klingenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara E.","family":"St\u00e4hli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dik","family":"Heg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5095-1523","authenticated-orcid":false,"given":"Andrea","family":"Denegri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Manka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Kapos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold","family":"von Eckardstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Carballo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian W.","family":"Hamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Vietheer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Rolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Landmesser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Mach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziano","family":"Moccetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malte","family":"Kelm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5503-4150","authenticated-orcid":false,"given":"Thomas","family":"M\u00fcnzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Pedrazzini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenz","family":"R\u00e4ber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian M.","family":"Matter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Ruschitzka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas F.","family":"L\u00fcscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2022.01.010_bib0001","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/cvr\/cvz050","article-title":"Immune cells as targets for cardioprotection: new players and novel therapeutic opportunities","volume":"115","author":"Andreadou","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ahj.2022.01.010_bib0002","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atherosclerosis","volume":"5","author":"Libby","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ahj.2022.01.010_bib0003","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.jacc.2016.01.073","article-title":"Inflammation as a driver of adverse left ventricular remodeling after acute myocardial infarction","volume":"67","author":"Westman","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ahj.2022.01.010_bib0004","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/ehjci\/jes271","article-title":"Final infarct size measured by cardiovascular magnetic resonance in patients with ST elevation myocardial infarction predicts long-term clinical outcome: an observational study","volume":"14","author":"L\u00f8nborg","year":"2013","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.ahj.2022.01.010_bib0005","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.jacc.2009.12.037","article-title":"Microvascular obstruction: underlying pathophysiology and clinical diagnosis","volume":"55","author":"Bekkers","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2022.01.010_bib0006","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2022.01.010_bib0007","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2022.01.010_bib0008","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1161\/CIRCULATIONAHA.121.056177","article-title":"Effect of colchicine on myocardial injury in acute myocardial infarction","volume":"144","author":"Mewton","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2022.01.010_bib0009","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/TP.0b013e31825b411c","article-title":"A comprehensive review of everolimus clinical reports: a new mammalian target of rapamycin inhibitor","volume":"94","author":"Gurk-Turner","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.ahj.2022.01.010_bib0010","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.vph.2018.12.004","article-title":"Everolimus depletes plaque macrophages, abolishes intraplaque neovascularization and improves survival in mice with advanced atherosclerosis","volume":"113","author":"Kurdi","year":"2019","journal-title":"Vasc Pharmacol"},{"key":"10.1016\/j.ahj.2022.01.010_bib0011","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nri2546","article-title":"Immunoregulatory functions of mTOR inhibition","volume":"9","author":"Thomson","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ahj.2022.01.010_bib0012","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/cmi.2014.24","article-title":"Effect of everolimus on the immunomodulation of the human neutrophil inflammatory response and activation","volume":"12","author":"Vitiello","year":"2015","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.ahj.2022.01.010_bib0013","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1016\/j.jacc.2009.08.031","article-title":"Beneficial effects of Mammalian target of rapamycin inhibition on left ventricular remodeling after myocardial infarction","volume":"54","author":"Buss","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2022.01.010_bib0014","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jacc.2019.05.024","article-title":"Cardiac MRI endpoints in myocardial infarction experimental and clinical trials: JACC scientific expert panel","volume":"74","author":"Ibanez","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2022.01.010_bib0015","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1148\/radiol.11102216","article-title":"Acute, subacute, and chronic myocardial infarction: quantitative comparison of 2D and 3D late gadolinium enhancement MR imaging","volume":"259","author":"Goetti","year":"2011","journal-title":"Radiology"},{"key":"10.1016\/j.ahj.2022.01.010_bib0016","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1093\/eurheartj\/ehx640","article-title":"Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes","volume":"38","author":"Klingenberg","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2022.01.010_bib0017","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1148\/radiol.11110228","article-title":"Timing of cardiovascular MR imaging after acute myocardial infarction: effect on estimates of infarct characteristics and prediction of late ventricular remodeling","volume":"261","author":"Mather","year":"2011","journal-title":"Radiology"},{"key":"10.1016\/j.ahj.2022.01.010_bib0018","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jacc.2009.04.021","article-title":"Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction","volume":"54","author":"Tsujioka","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2022.01.010_bib0019","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1161\/01.CIR.0000138935.17503.35","article-title":"Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial","volume":"110","author":"Hausleiter","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2022.01.010_bib0020","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.jacc.2005.12.052","article-title":"Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study","volume":"47","author":"Rodriguez","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2022.01.010_bib0021","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.jcin.2009.08.015","article-title":"Long-term risk of adverse outcomes and new malignancies in patients treated with oral sirolimus for prevention of restenosis","volume":"2","author":"Kufner","year":"2009","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2022.01.010_bib0022","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4244\/EIJV5I2A40","volume":"5","author":"Rodriguez","year":"2009","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ahj.2022.01.010_bib0023","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2022.01.010_bib0024","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N Engl J Med"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870322000102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870322000102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:58:40Z","timestamp":1762077520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870322000102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":24,"alternative-id":["S0002870322000102"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2022.01.010","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS) - A phase II, randomized, double-blind, multi-center, placebo-controlled trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2022.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}